New combo tackles lung cancer after immunotherapy fails
NCT ID NCT05407155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs—bevacizumab, nab-paclitaxel, and a platinum drug—as a second-line treatment for people with advanced non-squamous non-small cell lung cancer that does not have certain genetic mutations. The cancer must have worsened after first-line immunotherapy. The trial enrolls 56 participants and measures how many patients see their tumors shrink, as well as how long they live without the cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab plus nab-paclitaxel and platinum (carboplatin or cisplatin)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced lung cancer whose disease has progressed after initial immunotherapy.
- What could go wrong
- This is a small, early-phase study with only 56 participants, so results may not apply to everyone. The combination can cause serious side effects like bleeding, nerve damage, and kidney problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lung cancer drug designed for one mutation work for another?
- Could chemo plus immunotherapy double the punch against tough lung cancers?
- Should all advanced lung cancer patients get a brain scan? new trial aims to find out
- New hope for tough lung cancer? trial tests targeted drug against chemo
- New combo therapy for lung cancer under Real-World watch
- New cocktail targets lung cancer in the brain: triple therapy shows promise in early trial